Sandbox:Ifeoma Anaya: Difference between revisions
Jump to navigation
Jump to search
Sara Mohsin (talk | contribs) No edit summary |
Sara Mohsin (talk | contribs) No edit summary |
||
Line 1: | Line 1: | ||
{| class="wikitable" | {| class="wikitable" | ||
|+ | |+ | ||
!style="background:#4479BA; color: #FFFFFF;" align="center" + |classification | ! style="background:#4479BA; color: #FFFFFF;" align="center" + |classification | ||
!style="background:#4479BA; color: #FFFFFF;" align="center" + | | ! style="background:#4479BA; color: #FFFFFF;" align="center" + | | ||
!style="background:#4479BA; color: #FFFFFF;" align="center" + | | ! style="background:#4479BA; color: #FFFFFF;" align="center" + | | ||
!style="background:#4479BA; color: #FFFFFF;" align="center" + | | ! style="background:#4479BA; color: #FFFFFF;" align="center" + | | ||
! | |||
|- | |- | ||
| align="center" style="background:#DCDCDC;" + |SCC | | align="center" style="background:#DCDCDC;" + |SCC | ||
| | |||
| | | | ||
| | | | ||
Line 12: | Line 14: | ||
|- | |- | ||
| align="center" style="background:#DCDCDC;" + |BCC | | align="center" style="background:#DCDCDC;" + |BCC | ||
| | |||
| | | | ||
| | | | ||
Line 17: | Line 20: | ||
|- | |- | ||
| align="center" style="background:#DCDCDC;" + |Melanoma | | align="center" style="background:#DCDCDC;" + |Melanoma | ||
| | |||
| | |||
| | |||
| | |||
|- | |||
| | |||
| | |||
| | | | ||
| | | |
Revision as of 18:33, 28 August 2020
classification | ||||
---|---|---|---|---|
SCC | ||||
BCC | ||||
Melanoma | ||||
Practice here
Criteria | Symptomatic WM | Asymptomatic WM | IgM-Related Disorders | MGUS |
---|---|---|---|---|
IgM monoclonal protein | + | + | + | + |
Bone marrow infiltration | + | + | - | - |
Symptoms attributable to IgM | + | - | + | - |
Symptoms attributable to tumor infiltration | + | - | - | - |
References
- ↑ Kiran U, Aggarwal S, Choudhary A, Uma B, Kapoor PM (2017). "The blalock and taussig shunt revisited". Ann Card Anaesth. 20 (3): 323–330. doi:10.4103/aca.ACA_80_17. PMC 5535574. PMID 28701598.